Tandem Diabetes Care Inc (TNDM) stock
TNDMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3030% below fair value
$17.06−1.42 (-7.68%)
Close on Nov 17, 2026Market cap $1.19BP/E –Yield –
Tandem Diabetes Care r&d expenses
Research and development expenses are spending on new products and technology.
Tandem Diabetes Care's R&D Expenses for the twelve months ending Jun 30, 2026 was $187.75M, down 6.9% year over year. For fiscal 2025 it was $193.11M, down 2.9% from the year before. Over ten years it grew 27.5% a year on average. The highest annual figure on record is $198.88M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $193.11M | -2.9% |
| FY2024 | Dec 31, 2024 | $198.88M | +17.2% |
| FY2023 | Dec 31, 2023 | $169.67M | +22.0% |
| FY2022 | Dec 31, 2022 | $139.11M | +51.1% |
| FY2021 | Dec 31, 2021 | $92.05M | +44.8% |
| FY2020 | Dec 31, 2020 | $63.57M | +40.7% |
| FY2019 | Dec 31, 2019 | $45.20M | +54.6% |
| FY2018 | Dec 31, 2018 | $29.23M | +41.5% |
| FY2017 | Dec 31, 2017 | $20.66M | +9.8% |
| FY2016 | Dec 31, 2016 | $18.81M | +10.9% |
| FY2015 | Dec 31, 2015 | $16.96M | +7.4% |
| FY2014 | Dec 31, 2014 | $15.79M | +42.5% |
| FY2013 | Dec 31, 2013 | $11.08M | +23.0% |
| FY2012 | Dec 31, 2012 | $9.01M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $46.93M | -2.5% |
| Q1 FY2026 | Mar 31, 2026 | $46.04M | -8.3% |
| Q4 FY2025 | Dec 31, 2025 | $46.07M | -11.8% |
| Q3 FY2025 | Sep 30, 2025 | $48.72M | -4.7% |
| Q2 FY2025 | Jun 30, 2025 | $48.12M | -2.4% |
| Q1 FY2025 | Mar 31, 2025 | $50.22M | +8.6% |
| Q4 FY2024 | Dec 31, 2024 | $52.20M | +22.5% |
| Q3 FY2024 | Sep 30, 2024 | $51.11M | +21.8% |
| Q2 FY2024 | Jun 30, 2024 | $49.33M | +14.9% |
| Q1 FY2024 | Mar 31, 2024 | $46.24M | +9.7% |
| Q4 FY2023 | Dec 31, 2023 | $42.60M | +19.7% |
| Q3 FY2023 | Sep 30, 2023 | $41.97M | +14.1% |
| Q2 FY2023 | Jun 30, 2023 | $42.93M | +27.9% |
| Q1 FY2023 | Mar 31, 2023 | $42.16M | +27.1% |
| Q4 FY2022 | Dec 31, 2022 | $35.59M | +20.7% |
| Q3 FY2022 | Sep 30, 2022 | $36.80M | +52.7% |
| Q2 FY2022 | Jun 30, 2022 | $33.57M | +63.8% |
| Q1 FY2022 | Mar 31, 2022 | $33.16M | +84.6% |
| Q4 FY2021 | Dec 31, 2021 | $29.49M | +69.7% |
| Q3 FY2021 | Sep 30, 2021 | $24.10M | +49.8% |
| Q2 FY2021 | Jun 30, 2021 | $20.50M | +28.2% |
| Q1 FY2021 | Mar 31, 2021 | $17.96M | +27.2% |
| Q4 FY2020 | Dec 31, 2020 | $17.38M | +38.3% |
| Q3 FY2020 | Sep 30, 2020 | $16.09M | +33.7% |
| Q2 FY2020 | Jun 30, 2020 | $15.99M | +42.7% |
| Q1 FY2020 | Mar 31, 2020 | $14.12M | +50.4% |
| Q4 FY2019 | Dec 31, 2019 | $12.57M | +42.9% |
| Q3 FY2019 | Sep 30, 2019 | $12.04M | +50.5% |
| Q2 FY2019 | Jun 30, 2019 | $11.20M | +73.5% |
| Q1 FY2019 | Mar 31, 2019 | $9.39M | +57.1% |
| Q4 FY2018 | Dec 31, 2018 | $8.80M | +53.0% |
| Q3 FY2018 | Sep 30, 2018 | $8.00M | +62.8% |
| Q2 FY2018 | Jun 30, 2018 | $6.46M | +32.7% |
| Q1 FY2018 | Mar 31, 2018 | $5.98M | +16.5% |
| Q4 FY2017 | Dec 31, 2017 | $5.75M | +32.4% |
| Q3 FY2017 | Sep 30, 2017 | $4.91M | -20.1% |
| Q2 FY2017 | Jun 30, 2017 | $4.87M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.13M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.35M | – |
| Q3 FY2016 | Sep 30, 2016 | $6.15M | – |
See a number that looks wrong?